CBZ

CBIZ's FY2025 looks explosive on the surface — revenue +52.1% to $2.76B, net income +181.3% to $115M, diluted EPS up to $1.83 from $0.78 — but the MD&A is explicit that this is bought growth, not organic: 'Revenue from newly acquired operations, net of divestitures, contributed $914.2 million, or 50.4%, of incremental revenue.' Of the three practice groups, only Financial Services grew (the Marcum non-attest assets landing there), while Benefits & Insurance was roughly flat ($409.6M vs $401.0M) and National Practices shrank ($46.9M vs $49.9M). So the headline growth rate overstates the underlying franchise momentum, and the lumpy net-income history (FY2023 $121M, FY2024 $41M, FY2025 $115M) shows how integration costs and a doubling of D&A to $98.3M whipsaw GAAP earnings.

Quality and the balance sheet argue for caution. Margins are structurally thin for a 'professional services' premium — gross 12.9%, operating 8.5%, net 4.2% — and ROE is only 6.6%. The Marcum deal left $1,472.4M of debt under the 2024 Credit Facilities against just $18.3M of cash, with management openly targeting a net leverage ratio of only 2.0x–2.5x 'overtime' — i.e., deleveraging is a multi-year priority, not done. The Risk Factors flag two live concerns that the numbers can't yet disprove: that CBIZ 'may have underestimated the liabilities' assumed from Marcum, and the receivables/collection risk inherent to professional-services firms that 'may be magnified if the general economy worsens.'